The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

Just days after announcing sweeping job cuts at NHS England, UK Prime Minister Keir Starmer has said that the government ...

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

Merck (NYSE:MRK) announced the opening of a new $1 billion vaccine manufacturing facility in Durham, North Carolina, a major development aligning with the company's broader $12 billion U.S. investment ...

This expansion of our Durham plant is a crucial component of the more than $12 billion Merck has invested toward U.S. capital ...

Merck KGaA’s oral TLR7/8 inhibitor enpatoran has failed to meet the primary endpoint in a subgroup of patients, but ...

The decision made public on Tuesday by U.S. District Judge Kenneth Bell in Charlotte, North Carolina covers more than 200 ...

In a report released today, Matthew Weston from UBS maintained a Buy rating on Merck KGaA (0O14 – Research Report), with a price target of ...